Content Type: Research Publications

Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials

March 15, 2026

Competition and Price Among Brand-Name Drugs in the Same Class: A Systematic Review of the Evidence

March 15, 2026

Characteristics of Trials and Regulatory Pathways Leading to US Approval of Innovative vs. Non-Innovative Oncology Drugs

March 15, 2026

Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis

March 15, 2026

Design Characteristics, Risk of Bias, and Reporting of Randomised Controlled Trials Supporting Approvals of Cancer Drugs by European Medicines Agency, 2014-16: Cross Sectional Analysis

March 15, 2026

Transformative Models to Promote Prescription Drug Innovation and Access: A Landscape Analysis

March 15, 2026

Patients’ Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey

March 15, 2026

Application of Orphan Drug Designation to Cancer Treatments (2008-2017): A Comprehensive and Comparative Analysis of the USA and EU

March 15, 2026

Analysis of Proposed Medicare Part B to Part D Shift with Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs

March 15, 2026

Duration of Adjuvant Immunotherapy—Biologic, Clinical, and Economic Considerations

March 15, 2026

A Survey of Patients’ Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications

March 15, 2026

Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012

March 15, 2026